Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)

Abstract

A single intranasal vaccination with live attenuated virus provides protection against VOC B.1.1.7 (Alpha) and B.1.351 (Beta).

A live attenuated vaccine confers superior mucosal and systemic immunity to SARS-CoV-2 variants

“…Utilizing the widely employed mRNA vaccine BNT162b2 and two original vaccine candidates – an adenoviral vector vaccine carrying the spike glycoprotein of SARS-CoV-2 ( 28 ) and a live attenuated COVID-19 vaccine candidate named sCPD9 ( 29 , 30 ) – we assessed vaccine efficacy and mode of action in a heterologous SARS-CoV-2 Delta variant challenge setting.…”

“…We studied the efficacy of the BNT162b2 mRNA vaccine (Pfizer-BioNTech), adenovirus vector vaccine candidate Ad2-spike ( 28 ) and modified live attenuated SARS-CoV-2 vaccine candidate sCPD9 ( 29 , 30 ), as well as immune responses to vaccination and challenge in two consecutive and independent animal experiments. The infection experiments were done in the Syrian hamsters, a highly susceptible model for SARS-CoV-2 infection ( 70 ).…”

Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern

“… 10 , 11 The model have been effectively used for the studies on the vaccines, antivirals, pathogenesis, transmissibility, virus shedding and disease severity associated with SARS-CoV-2 VOC's. 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 Recently, few studies have been published on the pathogenesis aspect of Omicron variant in mice and Syrian hamsters in comparison with other VOC's demonstrating decreased severity of infection. 23 , 24 , 25 , 26 , 27 , 28 , 29 Abdelnabi et al.…”

Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals

“…However, NSP14-deficient mutants of MERS-CoV and SARS-CoV-2 are inviable [ 28 ]. A strategy of genome recoding has been used successfully to attenuate SARS-CoV-2 [ 29 – 31 ]. Generally consistent with the notion that compromising the expression of NSP16 might attenuate SARS-CoV-2, codon pair deoptimization of the NSP16 gene gave rise to a highly attenuated virus designated sCPD9 [ 30 , 31 ].…”

“…A strategy of genome recoding has been used successfully to attenuate SARS-CoV-2 [ 29 – 31 ]. Generally consistent with the notion that compromising the expression of NSP16 might attenuate SARS-CoV-2, codon pair deoptimization of the NSP16 gene gave rise to a highly attenuated virus designated sCPD9 [ 30 , 31 ]. In this study, we generated a recombinant SARS-CoV-2 strain carrying the NSP16 D130A mutation and demonstrated the feasibility of using NSP16 inactivation as a strategy for the development of live attenuated SARS-CoV-2 vaccines.…”